E-submission
Search
- Page Path
- HOME > Search
Original Article
- Special AT-rich sequence-binding protein 2 (SATB2) in the differential diagnosis of osteogenic and non-osteogenic bone and soft tissue tumors
- Sharon Milton, Anne Jennifer Prabhu, V. T. K. Titus, Rikki John, Selvamani Backianathan, Vrisha Madhuri
- J Pathol Transl Med. 2022;56(5):270-280. Published online September 13, 2022
- DOI: https://doi.org/10.4132/jptm.2022.07.11
- 7,283 View
- 135 Download
- 7 Web of Science
- 9 Crossref
-
Abstract
PDF - Background
The diagnosis of osteosarcoma (OSA) depends on clinicopathological and radiological correlation. A biopsy is considered the gold standard for OSA diagnosis. However, since OSA is a great histological mimicker, diagnostic challenges exist. Immunohistochemistry (IHC) can serve as an adjunct for the histological diagnosis of OSA. Special AT-rich sequence-binding protein 2 (SATB2) was recently described as a reliable adjunct immunohistochemical marker for the diagnosis of OSA.
Methods
We investigated the IHC expression of SATB2 in 95 OSA and 100 non-osteogenic bone and soft tissue tumors using a monoclonal antibody (clone EPNCIR30A). The diagnostic utility of SATB2 and correlation with clinicopathological parameters were analyzed.
Results
SATB2 IHC was positive in 88 out of 95 cases (92.6%) of OSA and 50 out of 100 cases (50.0%) of primary non-osteogenic bone and soft tissue tumors. Of the 59 bone tumors, 37 cases (62.7%) were positive for SATB2, and of the 41 soft tissue tumors, 13 cases (31.7%) were positive for SATB2. The sensitivity of SATB2 as a diagnostic test was 92.6%, specificity 50%, positive predictive value 63.8%, and negative predictive value 87.7%.
Conclusions
Although SATB2 is a useful diagnostic marker for OSA, other clinical, histological and immunohistochemical features should be considered for the interpretation of SATB2. -
Citations
Citations to this article as recorded by
- The diagnostic utility of SATB2 immunohistochemistry as an adjunct for differentiating osteogenic from non-osteogenic bone tumors: A systematic review and Meta-analysis
Yuchen Lou, Xuan Liu, Chenxiao Ma, Xin Liu
Bone.2026; 203: 117721. CrossRef - Immunohistochemical Characterization of Feline Giant Cell Tumor of Bone (GCTb): What We Know and What We Can Learn from the Human Counterpart
Ilaria Porcellato, Giuseppe Giglia, Leonardo Leonardi
Animals.2025; 15(5): 699. CrossRef - Epigallocatechin gallate impels osteogenic differentiation of human BMSCs by targeting the METTL3/SATB2/Wnt/β-catenin axis
Qiao Ren, Kang Chen, Lin Wang
Letters in Drug Design & Discovery.2025; 22(3): 100027. CrossRef - A case of cardiac undifferentiated pleomorphic sarcoma treated with post-operative radiotherapy followed by heart transplantation
Sungyeon Jung, Eun Na Kim, Hye In Lee, Hak Jae Kim, Jiwon Koh
Cardiovascular Pathology.2025; 79: 107760. CrossRef - Osteoblastic Osteosarcoma With Diverse Histomorphology: Diagnostic Insights From SATB2 and CD56 Immunoexpression
Padmaraj Hegde, Reshma Amin, Vijith Vittal Shetty, Pushparaja Shetty
Journal of Health and Allied Sciences NU.2025; 0: 1. CrossRef - High-throughput 3D engineered paediatric tumour models for precision medicine
MoonSun Jung, Valentina Poltavets, Joanna N Skhinas, Gabor Tax, Alvin Kamili, Jinhan Xie, Sarah Ghamrawi, Philipp Graber, Jie Mao, Marie Wong-Erasmus, Louise Cui, Kathleen Kimpton, Pooja Venkat, Chelsea Mayoh, Angela Lin, Emmy D G Fleuren, Ashleigh M Ford
Molecular Systems Biology.2025; 21(12): 1748. CrossRef - SATB2 immunohistochemistry in osteosarcoma: Utility in diagnosis and differentiation from histologic mimics
Supriya Gangula, Monalisa Hui, Shantveer G. Uppin, B Arvind Kumar, K Nageshwara Rao, B Rajeev Reddy, G Sadashivudu
Indian Journal of Pathology and Microbiology.2025; 68(3): 518. CrossRef - Early-onset metastatic fibroblastic osteosarcoma of the metatarsus in a young cat: a case report
Mojtaba Kiakojoori, Hossein Kazemi Mehrjerdi, Ali Mirshahi, Mahdieh Zaeemi, Mohsen Maleki
BMC Veterinary Research.2025;[Epub] CrossRef - Favorable treatment response to high‐grade sarcoma in neurofibromatosis 1
Michelle H. Talukder, Mauli M. Patel, Tala Al‐Saghir, Ghadir K. Katato, Janet Poulik, William J. Powell, Alysia K. Kemp, Steven Miller, Danielle Bell, Jeffrey W. Taub
Pediatric Blood & Cancer.2023;[Epub] CrossRef
- The diagnostic utility of SATB2 immunohistochemistry as an adjunct for differentiating osteogenic from non-osteogenic bone tumors: A systematic review and Meta-analysis
Case Report
- Spindle Cell Carcinoma in Larynx: A case showing bone formation.
- Hye Kyung Ahn, Hye Rim Park, Young Euy Park
- Korean J Pathol. 1993;27(3):293-295.
- 1,930 View
- 16 Download
-
Abstract
PDF
- Spindle cell carcinoma of the upper aerodigestive tract mucosa was usually presented as polypoid mass and shows squamous cell carcinoma or dysplasia in the surface and underlying spindle cell proliferation. The spindle cell area discloses a variable pattern of sarcoma including rare osteosarcoma of 0~20% incidence. The histogenetic origin of the spindle cell component is now considered a metaplasia of squamous cell carcinoma. We experienced a case of spindle cell carcinoma of larynx showing massive underlying bone formation with proliferation of osteoclast-like cells in 75 year-old man. The immunohistochemical study demonstrates positive reaction with cytokeratin in area of squamous cells and with vimentin in area of spindle cells and osteoclasts. There are very focal reactivity for high molecular weight cytokeratin in spindle cell area.
First
Prev
